1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab

• Richard A Furie,
• Eric F Morand,
• Sule Yavuz,
• Kenneth C Kalunian,
• Gabriel Abreu,
• Ronald van Vollenhoven,
• Catharina Lindholm,
• Hussein Al-Mossawi

Affiliations

Richard A Furie

Division of Rheumatology, Northwell Health, Great Neck, New York City, New York, USA

Eric F Morand

Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia

Sule Yavuz

1Uppsala University, Uppsala, Sweden

Kenneth C Kalunian

13University of California San Diego School of Medicine, La Jolla, CA, USA

Gabriel Abreu

Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Ronald van Vollenhoven

1Karolinska Institute, Department of Medicine, Division of Rheumatology and Early Arthritis Clinic of the Karolinska University Hospital, Stockholm, Sweden

Catharina Lindholm

BioPharmaceuticals R&D, AstraZeneca, Goteborg, Sweden

Hussein Al-Mossawi

Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA